Taking Cancer On Webinar – Let’s TOAST to Maximising
Time on EGFR-TKI Therapy (Lecture)
Speaker: Prof. Jin-Hyoung Kang
Document ID: PC-MY-102220
Watch Prof. Jin-Hyoung Kang as he discusses how
sequential approach with upfront GIOTRIF® (afatinib) is a feasible and cost-effective treatment
strategy for EGFR M+ NSCLC patients.
Speaker
Prof. Jin-Hyoung Kang
Professor of Medicine, Seoul St. Mary’s Hospital
Director in Medical Oncology Program, The Catholic University of Korea
Seoul, South Korea
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Q&A)
Speaker: Prof. Jin-Hyoung Kang
ESMO Asia 2021 – A Strategic Approach to Select and Sequence Therapies in EGFRm+ NSCLC
Speaker: Prof. Zhou Caicun